MPM funds trim Werewolf Therapeutics stake in 13D/A

Werewolf Therapeutics’ major MPM-affiliated investors filed Amendment No. 7 to Schedule 13D updating their ownership in the company’s common stock.

Rhea-AI Filing Summary

Werewolf Therapeutics’ major MPM-affiliated investors filed Amendment No. 7 to Schedule 13D updating their ownership in the company’s common stock. The filing shows various MPM funds and related entities holding individual stakes ranging from 0.1% to 3.8% of outstanding shares.

As of May 1, 2026, the ownership percentages are calculated against 48,596,817 shares of Werewolf Therapeutics common stock. The reporting group sold blocks of shares in open-market transactions between May 6 and May 12, 2026 at average prices generally around $0.63–$0.70 per share.

Key Figures

Shares Outstanding: 48,596,817 shares BV 2014 Stake: 792,254 shares (1.6%) UBS Oncology Stake: 655,471 shares (1.3%) +4 more

7 metrics

Shares Outstanding 48,596,817 shares Common stock outstanding as of May 1, 2026

BV 2014 Stake 792,254 shares (1.6%) Held by MPM BioVentures 2014, L.P. with sole voting and dispositive power

UBS Oncology Stake 655,471 shares (1.3%) Held by UBS Oncology Impact Fund L.P. with sole voting and dispositive power

Ansbert Gadicke Ownership 1,826,646 shares (3.8%) Aggregate beneficial ownership with shared voting and dispositive power

MPM OIF Stake 173,334 shares (0.4%) Held by MPM Oncology Innovations Fund L.P. with sole voting and dispositive power

Sample Sale on May 8, 2026 $0.70 average price Open-market sales on 05/08/26 within $0.6183–$0.7668 range

Sample Sale on May 7, 2026 $0.63 average price Open-market sales on 05/07/26 within $0.62–$0.667 range

Key Terms

beneficially own, aggregate amount beneficially owned, sole voting power, shared dispositive power, +1 more

5 terms

beneficially own financial

"may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B)"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

aggregate amount beneficially owned financial

"11Aggregate amount beneficially owned by each reporting person 792,254.00"

sole voting power financial

"7 | Sole Voting Power 792,254.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"10 | Shared Dispositive Power 1,826,646.00"

open market financial

"The Reporting Persons sold the following Common Stock in the open market since Amendment No. 6"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Werewolf Therapeutics (HOWL) Schedule 13D/A filing show about MPM ownership?

The filing shows several MPM-affiliated funds and individuals reporting updated beneficial ownership in Werewolf Therapeutics common stock, with individual positions ranging from about 0.1% up to 3.8% of outstanding shares, calculated against 48,596,817 shares as of May 1, 2026.

How many Werewolf Therapeutics (HOWL) shares does Ansbert Gadicke report owning?

Ansbert Gadicke reports beneficial ownership of 1,826,646 Werewolf Therapeutics common shares, representing about 3.8% of the class. These shares are held indirectly through various MPM-related investment entities over which he has management roles, as described in the ownership footnotes.

What stake in Werewolf Therapeutics (HOWL) is reported for UBS Oncology Impact Fund L.P.?

UBS Oncology Impact Fund L.P. reports beneficial ownership of 655,471 Werewolf Therapeutics common shares, representing about 1.3% of the outstanding stock. Control is attributed through BioImpact and Oncology Cayman as direct and indirect general partners of UBS Oncology Impact Fund L.P.

What Werewolf Therapeutics (HOWL) share sales are disclosed in the May 2026 Schedule 13D/A amendment?

The reporting persons disclose open-market sales of common stock between May 6 and May 12, 2026, with various MPM funds selling shares at average prices around $0.63–$0.70 per share. Each fund’s daily share amounts and price ranges are itemized in the transaction table.

How many Werewolf Therapeutics (HOWL) shares does MPM BioVentures 2014, L.P. hold?

MPM BioVentures 2014, L.P. reports holding 792,254 Werewolf Therapeutics common shares, equal to about 1.6% of the class. The partnership has sole voting and dispositive power over these shares, according to the ownership table in the amendment.

What is the reported total share count used for ownership percentages in the Werewolf Therapeutics (HOWL) filing?

Ownership percentages are calculated using 48,596,817 Werewolf Therapeutics common shares outstanding as of May 1, 2026. That share count comes from the company’s Form 10-Q filed on May 7, 2026, which the reporting group cites as its basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 07:56 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

WEREWOLF THERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

95075A107

(CUSIP Number)

Ansbert Gadicke
c/o MPM BioImpact LLC, 339 Boylston Street, Suite 1100
Boston, MA, 02116
617-425-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/08/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM BioVentures 2014, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 792,254.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 792,254.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

792,254.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM BioVentures 2014 (B), L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 52,840.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 52,840.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

52,840.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM Asset Management Investors BV2014 LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 27,267.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 27,267.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

27,267.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

UBS Oncology Impact Fund L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 655,471.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 655,471.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

655,471.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.3 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM BioVentures 2014 GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 845,094.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 845,094.00

11

Aggregate amount beneficially owned by each reporting person

845,094.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.7 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM BioVentures 2014 LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 872,361.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 872,361.00

11

Aggregate amount beneficially owned by each reporting person

872,361.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.8 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

Oncology Impact Fund (Cayman) Management L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 655,471.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 655,471.00

11

Aggregate amount beneficially owned by each reporting person

655,471.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.3 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 655,471.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 655,471.00

11

Aggregate amount beneficially owned by each reporting person

655,471.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.3 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

ANSBERT GADICKE

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,826,646.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,826,646.00

11

Aggregate amount beneficially owned by each reporting person

1,826,646.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

LUKE EVNIN

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,171,175.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,171,175.00

11

Aggregate amount beneficially owned by each reporting person

1,171,175.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.4 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

Todd Foley

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 872,361.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 872,361.00

11

Aggregate amount beneficially owned by each reporting person

872,361.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM ASSET MANAGEMENT LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 125,480.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 125,480.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

125,480.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM ONCOLOGY INNOVATIONS FUND LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 173,334.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 173,334.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

173,334.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.4 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 95075A107

1

Name of reporting person

MPM Oncology Innovations Fund GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 173,334.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 173,334.00

11

Aggregate amount beneficially owned by each reporting person

173,334.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.4 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: WEREWOLF THERAPEUTICS, INC.
(c)	Address of Issuer's Principal Executive Offices: 200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN, MASSACHUSETTS , 02472.
Item 1 Comment: Explanatory Note: This Amendment No. 7 to Schedule 13D ("Amendment No. 7") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of Werewolf Therapeutics Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the "SEC") on May 14, 2021 and as amended by Amendment No. 1 filed November 4, 2025, Amendment No. 2 filed November 17, 2025, Amendment No. 3 filed December 3, 2025, Amendment No. 4 filed December 29, 2025, Amendment No. 5 filed January 16, 2026 and Amendment No. 6 filed May 5, 2026 (as amended, the "Original Schedule 13D"). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Stock by certain Filing Persons. Items 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 7 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 7 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person. The Common Stock is held as follows: * 792,254 shares are held directly by BV 2014; * 52,840 shares are held directly by BV 2014(B); * 27,267 shares are held directly by AM BV2014 LLC; * 173,334 shares are held directly by MPM OIF; * 125,480 shares by AM LLC; and * 655,471 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. MPM OIF GP is the general Partner of MPM OIF and, accordingly, may be deemed to beneficially own the shares held by MPM OIF. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Drs. Gadicke and Evnin are the members of AM LLC and managers of MPM OIF GP and, accordingly, may be deemed to beneficially own the shares held by AM LLC and MPM OIF. Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 48,596,817 shares of Common Stock outstanding as of May 1, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 7, 2026.
(b)	See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 7 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.
(c)	The Reporting Persons sold the following Common Stock in the open market since Amendment No. 6: Date of Price Range Ave. Price Sold by Sold by Sold By Sold by Sold by Sold by Sale BV 2014 BV AM BV2014 MPM OIF AM LLC UBS 2014(B) LLC Oncology 05/06/26 $0.65-$0.7054 $0.66 9,900 660 341 2,166 1,568 8,190 05/07/26 $0.62-$0.667 $0.63 53,499 3,568 1,841 11,705 8.473 44,262 05/08/26 $0.6183-$0.7668 $0.70 206,820 13,795 7,119 45,250 32,757 171,114 05/11/26 $0.66-$0.7002 $0.67 22,965 1,532 790 5,024 3,637 19,000 05/12/26 $0.6286-$0.66 $0.64 45,921 3,063 1,581 10,047 7,273 37,994
(d)	Inapplicable.
(e)	May 8, 2026
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.C - Joint Filing Statement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioVentures 2014, L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P.
Date:	05/12/2026

MPM BioVentures 2014 (B), L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P.
Date:	05/12/2026

MPM Asset Management Investors BV2014 LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC
Date:	05/12/2026

UBS Oncology Impact Fund L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
Date:	05/12/2026

MPM BioVentures 2014 GP LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC
Date:	05/12/2026

MPM BioVentures 2014 LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director
Date:	05/12/2026

Oncology Impact Fund (Cayman) Management L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P.
Date:	05/12/2026

MPM BioImpact LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Partner
Date:	05/12/2026

ANSBERT GADICKE

Signature:	/s/ Ansbert Gadicke
Name/Title:	Ansbert Gadicke
Date:	05/12/2026

LUKE EVNIN

Signature:	/s/ Luke Evnin
Name/Title:	Luke Evnin
Date:	05/12/2026

Todd Foley

Signature:	/s/ Todd Foley
Name/Title:	Todd Foley
Date:	05/12/2026

MPM ASSET MANAGEMENT LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Member
Date:	05/12/2026

MPM ONCOLOGY INNOVATIONS FUND LP

Signature:	/s/ Ansbert Gadicke
Name/Title:	Manager of MPM Oncology Innovations Fund GP LLC, the General Partner of MPM Oncology Innovations Fund, L.P.
Date:	05/12/2026

MPM Oncology Innovations Fund GP LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Manager
Date:	05/12/2026